ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Educational Symposium

HIF-PH Inhibitors: Moving Beyond Erythropoietin and Iron Deficiency

October 24, 2020 | 01:00 PM - 02:00 PM

Location: Simulive

Session Description

Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors are the first novel class of medications to treat anemia since the approval of erythropoietin-stimulating agents in 1989. HIF-PH inhibitors are oral agents that treat anemia of CKD through multiple pathways; they have effects on inflammation and iron handling and decrease hepcidin levels. Advantages of HIF-PH inhibitors include decreased erythropoietin levels, increased absorption of oral iron, and access to existing iron stores.

Results of Phase 3 trials of HIF-PH inhibitors for the treatment of anemia in both dialysis-dependent and non–dialysis-dependent CKD have been promising. This symposium discusses the results of clinical trials and provides recommendations on the role of HIF-PH inhibitors in managing anemia of CKD.

Support is provided by an educational grant from Akebia Therapeutics, Inc. and Otsuka America Pharmaceutical, Inc.

Learning Objective(s)

  • Compare the advantages and disadvantages of HIF-PH inhibitors with those of erythropoietin-stimulating agents for the management of anemia in CKD
  • Determine the place for HIF-PH inhibitors in the management of anemia in CKD

Learning Pathway(s)

  • Bone and Mineral Metabolism
  • Chronic Kidney Disease

Moderator

  • Jeffrey S. Berns, MD, FASN

Presentations

  • Introduction
    01:00 PM - 01:10 PM
    Jeffrey S. Berns, MD, FASN
  • Efficacy and Safety of HIF-PH Inhibitors in Treating Anemia of Non-Dialysis-Dependent CKD
    01:10 PM - 01:35 PM
    Francesco Locatelli, MD
  • Efficacy and Safety of HIF-PH Inhibitors in Treating Anemia of Dialysis-Dependent CKD
    01:35 PM - 02:00 PM
    Kai-Uwe Eckardt, MD